Results 191 to 200 of about 153,102 (279)

Unveiling BCL-xL-specific PROTAC efficiency and dissociation pathways using native mass spectrometry. [PDF]

Chem Sci
Gadallah MI, Nonhof KL, Nayak D, Zhang P, Dioli O, Zheng G, Olsen SK, Zhou D, Brodbelt JS.   +8 more
europepmc   +1 more source

Integrated Molecular Docking and Gene Expression Analyses Suggest a Potential Interaction Between Diphtheria Toxin and Bcl‐2 in HT‐29 Colorectal Cancer Cells

Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 6, June 2026.
This study explores the interaction between Diphtheria Toxin (DT) and Bcl‐2 in HT‐29 cells. Integrating molecular docking with gene expression analysis, we demonstrate DT's high‐affinity binding to Bcl‐2 and a significant downregulation of BCL2 mRNA. These findings suggest that DT modulates anti‐apoptotic pathways, influencing colorectal cancer cell ...
Elif Ercan, Tugba Yalcinkaya, Belkis Levent, Ahmet Carhan   +3 more
wiley   +1 more source

PROTAC-mediated degradation of Bcl-xL potentiates target therapy in preclinical melanoma models. [PDF]

J Exp Clin Cancer Res
Valentini E, Gentile G, Di Martile M, D'Aguanno S, Brignone M, Di Stefano AM, Di Caprio M, Melucci E, Botti C, Pelle F, Ortolano A, Fattore L, Mancini R, Ciliberto G, Rotili D, Del Bufalo D.   +15 more
europepmc   +1 more source

Gut Microbiota‐Linked Benefits of Low‐Intensity Pulsed Ultrasound Rejuvenate the Ageing Muscle

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 3, June 2026.
ABSTRACT Background Ageing is an inevitable biological process that contributes to increased prevalence of age‐associated diseases, including sarcopenia, defined by progressive loss of muscle mass, functional decline and a heightened risk of injury. Developing effective interventions remains a critical clinical priority.
Jia‐Hua Jhuang, Kuo‐Cheng Lan, Ting‐Yu Chang, Ding‐Cheng Chan, Shing‐Hwa Liu   +4 more
wiley   +1 more source

The Combination of a BCL-xL PROTAC and an mTOR Inhibitor Sensitizes Pancreatic Ductal Adenocarcinoma to KRAS^G12D Inhibitor Treatment. [PDF]

Cancers (Basel)
Miyan J, Vudatha V, Cao L, Zhang P, Zheng G, Zheng L, Trevino J, Zhou D, Khan S.   +8 more
europepmc   +1 more source

Cell Membrane Vesicles Encapsulating Il24 mRNA With Enriched CD6 Display Exhibit Enhanced Targeted Antitumor Efficacy

Journal of Extracellular Vesicles, Volume 15, Issue 6, June 2026.
ABSTRACT mRNA‐based therapeutics offer significant potential for cancer treatment owing to their ability to induce transient, non‐integrating expression of therapeutic proteins. However, effective and tumour‐specific delivery remains a major barrier.
Dandan Wang, Ruofan Gao, Duo Liu, Kefan Li, Runkai Wang, Minghe Xu, Shiwei Zhang, Shengjie Jiang, Bin Xia   +8 more
wiley   +1 more source

A Novel CIP2A and BCL-XL Clinical Diagnostic Toolkit to Predict Disease Progression and Treatment-Free Remission in Chronic Myeloid Leukaemia. [PDF]

Int J Mol Sci
Basabrain AA, Austin GM, Holcroft AK, Apperley JF, Clark RE, Varadarajan S, Lucas CM.   +6 more
europepmc   +1 more source

Intranasal Delivery of Bacterial Extracellular Vesicles Enables RNA Cargo Entry Into the Brain

Journal of Extracellular Vesicles, Volume 15, Issue 6, June 2026.
ABSTRACT Extracellular vesicles (EVs) released by bacteria are potent mediators of host–microbe interactions. They modulate immune responses, deliver functional molecules and influence disease progression. However, whether bacterial EVs can access the brain and functionally affect host cells remains unclear.
Jae Yeong Ha, So‐Mi Kim, Song‐Yi Choi, Chanyong Park, Sungsu Park, Su‐Hyung Hong, Il‐Sung Jang, Youngkyun Lee, Heon‐Jin Lee   +8 more
wiley   +1 more source

Targeting Bcl-xL to eliminate chemotherapy-induced tumor dormancy and prevent breast cancer metastasis. [PDF]

Br J Cancer
Gupta K, Koelsch N, Neely V, Graham L, Bear HD, Idowu MO, Harada H, Manjili MH.   +7 more
europepmc   +1 more source

Efficacy and Safety of Azacitidine Combined With Lisaftoclax in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome With Increased Blasts

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Objective To retrospectively analyze the early efficacy and safety of azacitidine plus lisaftoclax in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome with increased blasts (MDS‐IB), providing a reliable clinical reference.
Shan Meng, Wanhong Zhao, Hui Zhang, Bo Lei, Wanggang Zhang, Yilin Zhang, Jin Wang, Yinxia Chen, Xingmei Cao, Liufang Gu   +9 more
wiley   +1 more source